Indian API maker and consumer-health company: bulk drugs, branded formulations, and diagnostic devices.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 90 | 90 | 96 | 102 | 102 | 110 | 110 | 110 |
| Reserves | 194 | 335 | 483 | 651 | 745 | 1.0k | 1.1k | 1.1k |
| Borrowings | 133 | 17 | 19 | 25 | 29 | 105 | 158 | 208 |
| Other Liabilities | 246 | 416 | 473 | 332 | 417 | 517 | 381 | 482 |
| Total Liabilities | 663 | 858 | 1.1k | 1.1k | 1.3k | 1.8k | 1.7k | 1.9k |
| AssetsFixed Assets | 216 | 225 | 252 | 267 | 307 | 489 | 471 | 513 |
| CWIP | 0 | 2 | 14 | 17 | 24 | 28 | 26 | 22 |
| Investments | 1 | 1 | 0 | 0 | 1 | 85 | 136 | 124 |
| Other Assets | 446 | 631 | 804 | 827 | 960 | 1.2k | 1.1k | 1.3k |
| Total Assets | 663 | 858 | 1.1k | 1.1k | 1.3k | 1.8k | 1.7k | 1.9k |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 17 | 11 | 51 | -60 | -91 | 73 | 32 | 33 |
| Cash from Investing | -13 | -12 | -70 | -32 | -47 | -83 | -322 | -123 |
| Cash from Financing | 0 | 5 | 47 | 66 | 144 | 5 | 300 | 97 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | 6 | -6 | 10 | -127 | -137 | -8 | -182 | -127 |
| FCF Margin | — | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (32.4×) and current (39.1×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 21.5% growth and a 32× exit, ₹50 only delivers your return if you pay ₹48. The price is currently baking in 22% growth.
EPS grows 21.5%/yr for 5 years, then fades to 6% over 2, exits at 32×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 21.5% | 1.53 |
| FY28 | 21.5% | 1.86 |
| FY29 | 21.5% | 2.26 |
| FY30 | 21.5% | 2.75 |
| FY31 | 21.5% | 3.34 |
| FY32 | 13.8% ·fade | 3.79 |
| FY33 | 6.0% ·fade | 4.02 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.